Evidence map›Paper›PMID 36092841›Full record

ArticleTranslational andrology and urology2022

Intralesional collagenase

Ming-Yeah Y Hu, John T Sigalos, Dyvon T Walker, Michelle K Li, Dar A Yoffe, Neilufar Modiri, Thomas W Gaither, Alvaro J Santamaria, Keith V Regets, Sriram V Eleswarapu and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ming-Yeah Y HuDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
John T SigalosDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Dyvon T WalkerDivision of Urology, Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
Michelle K LiDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Dar A YoffeDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Neilufar ModiriDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Thomas W GaitherDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Alvaro J SantamariaDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Keith V RegetsDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Sriram V EleswarapuDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Jesse N MillsDivision of Andrology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
University of California, Los Angeles · USUniversity of Colorado Denver · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Peyronie's disease (PD) can be subdivided into acute and chronic phases. Intralesional collagenase Methods: All men receiving intralesional collagenase for PD from October 2015 through December 2020 at a single academic institution were retrospectively assessed for patient demographics and comorbidities, pre- and post-treatment curvature, and adverse events. Two definitions of acute phase were used: (I) acute phase duration ≤6 months, chronic phase duration >6 months; and (II) acute phase duration ≤12 months with penile pain, chronic phase duration >12 or no penile pain. Results: Of 330 patients identified, 229 underwent intralesional collagenase treatment with pre- and post-treatment erect penile goniometry. 65 (28%) met criteria for definition 1 of acute phase, 37 (16%) met criteria for definition 2, and 76 (33%) met criteria for either. Percent change in penile curvature was not significantly different between acute and chronic phases using definition 1 (16.0% Conclusions: This single-center, retrospective cohort analysis suggests that intralesional collagenase is both safe and effective for the treatment of men with acute phase PD. Limitations exist inherent to retrospective review, since many men did not return for post-treatment goniometry, possibly skewing our cohort toward incomplete responders. Prospective, randomized studies will be required to confirm these findings.

Indexed as

acute phasecollagenase Clostridium histolyticumPeyronie’s disease (PD)

Identifiers

PMID36092841
PMCPMC9459553
OpenAlexW4290702566

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.